TMC-310911

Also Known As:

((3aS,4R,6aR)-2,3,3a,4,5,6a-Hexahydrofuro(2,3-b)furan-4-yl) N-((1S,2R)-1-benzyl-3-((2-((1-cyclopentyl-4-piperidyl)amino)-1,3-benzothiazol-6-yl)sulfonyl-isobutyl-amino)-2-hydroxy-propyl)carbamate; ASC-09; ASC09; TMC310911

Networked: 3 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Liang, Lijun: 1 article (02/2021)
2.	Liu, Jian: 1 article (02/2021)
3.	Qiu, Yunqing: 1 article (02/2021)
4.	Zhai, You: 1 article (02/2021)
5.	Zhao, Qingwei: 1 article (02/2021)
6.	Zhu, Danyan: 1 article (02/2021)
7.	Adewumi, Adeniyi T: 1 article (11/2020)
8.	Omolabi, Kehinde F: 1 article (11/2020)
9.	Soliman, Mahmoud Es: 1 article (11/2020)
10.	Soremekun, Opeyemi S: 1 article (11/2020)

Related Diseases

1.	COVID-19 11/09/2020 - "Although there are conflicting clinical results on the therapeutic potency of RVT in the treatment of coronavirus disease 2019, our findings provided molecular insight into the binding mechanism of TMC-310911 and RVT with SARS-CoV-2 and SARS-CoV main proteases." 02/01/2021 - "In this work, the binding mechanisms of five protease inhibitors (e.g., danoprevir, darunavir, ASC09, lopinavir and ritonavir) to COVID-19 Mpro were investigated. "
2.	Infections 12/01/2011 - "The activity against a comprehensive panel of PI-resistant mutants and the limited in vitro selection of resistant viruses under drug pressure suggest that TMC310911 represents a potential drug candidate for the management of HIV-1 infection for a broad range of patients, including those with multiple PI resistance."

Related Drugs and Biologics

1.	Protease Inhibitors (Protease Inhibitor)
2.	Peptide Hydrolases (Proteases)
3.	Darunavir (Prezista)
4.	lopinavir-ritonavir drug combination (Kaletra)
5.	danoprevir